Regeneron Found by British High Court to Infringe Genentech Patent—Products Treat Macular Degeneration

摘要

LONDON, U.K. 4/4/12—The British High Court has found that Regeneron's Eylea (afibercept; VEGF Trap Eye) infringes a patent held by Genentech, Inc. (South San Francisco, Cal.): The products are treatments for wet age-related macular degeneration.Regeneron and Bayer, a licensee of the patent for most of the world, had filed separate suits asking for revocation of European Patent (U.K.) 1 238 986 and asked the court find they were not infringing with their product.